Mi Meng
Bo Yu
Jie Luo3
Shicheng Chen
Sisi He
Hu Ma
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 2Department of Urology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 3Department of Radiation Oncology, Guiqian International General Hospital, Guiyang, China
A Corrrigendum on
Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma
By Meng M, Yu B, Luo J, Bai Y, Li L, Chen S, He S and Ma H (2024). Front. Oncol. 14:1326006. doi: 10.3389/fonc.2024.1326006
In the published article, there was an error in affiliation 1. Instead of “Department of Thoracic Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, China”, it should be “Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: sintilimab, thymic carcinoma(TC), therapeutic option, case report, anti-PD-1
Citation: Meng M, Yu B, Luo J, Bai Y, Li L, Chen S, He S and Ma H (2024) Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma. Front. Oncol. 14:1516024. doi: 10.3389/fonc.2024.1516024
Received: 23 October 2024; Accepted: 25 November 2024;
Published: 02 December 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Meng, Yu, Luo, Bai, Li, Chen, He and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hu Ma, bWFodWFiQDE2My5jb20=; Sisi He, c2lzaWhlMTIxOUAxNjMuY29t
†These authors have contributed equally to this work and share first authorship